Imperva Data Security Fabric Provides Bold New Approach to Securing All Data in Multicloud and Hybrid Environments
5.4.2022 15:00:00 EEST | Business Wire | Press release
Imperva, Inc., (@Imperva) the comprehensive digital security leader, introduces the Imperva Data Security Fabric (DSF) to modernize and simplify data governance, security, and workflow management for all data across multicloud and hybrid environments. Imperva DSF standardizes data security controls across enterprise environments to provide full visibility of what is happening across all file stores and assets, on-premises, and across clouds. Its flexible architecture supports a wide range of data repositories, ensuring security policies are applied consistently everywhere.
Imperva DSF integrates Imperva Sonar and a deep portfolio of industry-leading and mission critical Imperva Data Security products and technologies. Customers are already using Imperva DSF capabilities to secure data in hundreds of data stores across leading cloud providers. These capabilities provide access to thousands of automation and response integrations to streamline visibility, create specific rules for managing data risk, and leverage a mix of security tools supporting those platforms.
Imperva DSF makes it easier for customers to understand and mitigate data risk at every step of their security journey across structured, semi-structured, and unstructured data. According to Gartner, “by 2024, larger enterprises will triple the unstructured data stored as file or object storage on-premises, at the edge or in the public cloud, compared with 2020. This massive growth in unstructured data demands better protection against threats such as ransomware.1” Imperva DSF can discover and classify more than 350 unique file formats, including the most widely used formats by Adobe, Google, Microsoft, and many others. Imperva DSF protects a customer’s multicloud and hybrid environments and provides visibility through a single service that can run anywhere within that environment. Imperva DSF provides a holistic view that makes it easier for customers to quickly identify and secure sensitive information across their entire protected environment.
Across a broad range of areas including policy compliance, compromised credentials, unintentional misuse, and malicious threats to sensitive data, organizations in all industries around the world are asking for our help to protect their data. They need broad but centralized control and automation for a more comprehensive view of risk posture, faster insights to accelerate response times, and reduced cost of ownership,” says Dan Neault, SVP and GM, Data Security, Imperva. “Imperva Data Security Fabric enables organizations to safeguard their sensitive data while ensuring data security, compliance, and privacy, and managing digital risk while confidently moving strategic data to the cloud.”
Imperva DSF and its unique automation capabilities for agent and agentless deployments makes it simpler and lower cost for customers to scale data governance and protection anywhere. "After going through a painful situation with another Data Activity Monitoring solution, we went with Imperva because we needed to deliver something quickly for compliance reasons. Imperva offered us a more efficient agent-based solution in terms of cost, management and a lot less complexity. You get to do everything in a single place,” says Diego Laverde, CISO of Banco Popular Dominicano. “It went into production seamlessly, the business didn’t even realize that it had happened, and it worked as it should.”
Through the Imperva Technology Alliance Program (TAP), Imperva DSF has built-in integrations with the world’s leading hyperscalers (e.g., Amazon Web Services™, Microsoft® Azure®, Google Cloud™, etc.), database vendors (e.g., Microsoft®, MongoDB® Atlas, Oracle DBMS, Snowflake™, etc.), and workflow managers (e.g., Atlassian, ServiceNow™, etc.). Imperva DSF opens up new partner-builder innovation opportunities to provide customers additional capabilities and simplify their orchestration. Imperva TAP is pleased to welcome Mage™ (formerly Mentis), a data masking alternative to Imperva DSF built-in capabilities to help customers secure structured and unstructured data throughout the development lifecycle.
“We are excited about the possibilities Imperva DSF enables for mutual customers and the partner ecosystem,” says Rajesh Parthasarathy, CEO of Mage. “Our technology alliance with Imperva provides organizations with an analyst-recognized integrated masking solution for all data types supported by the Imperva DSF.”
Imperva Data Security Fabric includes:
- Data Activity Monitoring: mitigate malicious insiders and external threats by detecting changes, auditing activities for compliance, and blocking or alerting on policy violations.
- Data Risk Analytics: automate detection of non-compliant, risky, or malicious data access behavior across data stores.
- Data Governance: discover and classify sensitive data residing in structured, semi-structured, and unstructured data types, to operationalize security control policies.
- Data Access Control: control user rights to sensitive data, including detecting overly-broad data access in the cloud or on-premises.
- Data Masking: transform data so it is either unreadable or de-identified, allowing processing to happen in compliance.
Additional Information:
- Learn more about the Imperva Technology Alliance Partner Program and apply to join
- Watch the explainer video Imperva Data Security Fabric
- Explore Imperva Data Security
- Check out the Imperva Blog for the latest products and solutions news, and threat intelligence from Imperva Threat Research
GARTNER is registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved
About Imperva
Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.
© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.
1Gartner Hype Cycle for Storage and Data Protection Technologies, Julie Palmer, 22 July 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005023/en/
Contact information
Erik Kingham
erik.kingham@imperva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release
Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
